KLRS Kalaris Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1754068 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY21.8%
TTM EPS YoY90.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-97.2%
ROA-51.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets46.7%
Debt / equity0.00x
Current ratio10.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.93x
Accruals ratio-3.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $8.34M | $9.02M | $7.57M | $7.16M | $9.13M | $8.44M | $6.03M | -$28.85M |
| SG&A expense | $3.47M | $3.37M | $4.26M | $3.64M | $3.62M | $3.82M | $4.32M | $3.28M |
| Operating income | -$11.81M | -$12.39M | -$11.83M | -$10.80M | -$12.74M | -$12.26M | -$10.35M | -$7.13M |
| Interest expense | $0 | $0 | $0 | $0 | $0 | $0 | $1.44M | $1.31M |
| Income tax | — | — | — | — | — | — | — | $0 |
| Net income | -$11.03M | -$11.52M | -$10.86M | -$10.00M | -$11.89M | -$11.35M | -$10.20M | -$22.03M |
| EBITDA | -$11.80M | -$12.38M | -$11.82M | -$10.79M | — | — | — | — |
| EPS (basic) | -0.46 | -0.48 | -0.46 | — | -0.64 | -0.61 | -2.52 | — |
| EPS (diluted) | -0.46 | -0.48 | -0.46 | — | -0.64 | -0.61 | -2.52 | — |
| Weighted avg. shares (diluted) | 23.80M | 23.80M | 23.72M | — | 18.70M | 18.70M | 4.05M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $47.38M | $43.17M | $34.43M | $98.05M | $42.39M | $88.43M | $100.97M | $1.64M |
| Short-term investments | $35.47M | $50.37M | $62.79M | $19.93M | $34.61M | — | — | $0 |
| Current assets | $85.18M | $95.92M | $98.47M | $118.81M | $78.18M | $91.65M | $102.18M | $2.61M |
| Total assets | $89.00M | $99.54M | $109.81M | $121.74M | $81.17M | $92.84M | $103.09M | $6.16M |
| Current liabilities | $8.51M | $8.74M | $8.08M | $9.71M | $6.07M | $7.65M | $7.14M | $24.70M |
| Total liabilities | $41.60M | $41.87M | $41.25M | $42.92M | $39.31M | $39.73M | $39.22M | $56.78M |
| Shareholders' equity | $47.40M | $57.67M | $68.56M | $78.81M | $41.87M | $53.12M | $63.87M | -$96.62M |
| Shares outstanding | 23.80M | 23.80M | 22.99M | 22.90M | 18.70M | 18.70M | 18.70M | 1.36M |
| Cash flow statement | ||||||||
| Operating cash flow | -$10.55M | -$11.05M | -$11.58M | -$7.06M | -$11.33M | -$12.54M | -$7.44M | -$7.85M |
| Capital expenditure | — | — | — | $17,000 | — | — | — | — |
| Free cash flow | — | — | — | -$7.07M | — | — | — | — |
| Investing cash flow | $14.84M | $20.17M | -$50.35M | $14.98M | — | — | — | $5.00M |
| Financing cash flow | -$75,000 | -$377,000 | -$1.70M | $47.74M | $0 | $0 | $107.27M | $7.58M |
| Depreciation & amortization | $10,000 | $10,000 | $10,000 | $10,000 | — | — | — | — |
| Stock-based compensation | $752,000 | $644,000 | $580,000 | $333,000 | $638,000 | $591,000 | $374,000 | $280,000 |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.